According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...
According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...
The US FDA has granted approval for AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for ...
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on ...
The FDA has approved at-home self- or caregiver-administration of FluMist (influenza vaccine live, intranasal).
FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...
AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...
The US Food and Drug Administration (FDA) has approved AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for self-administration. The approval makes FluMist the only 'flu vaccine ...
The FluMist vaccine, manufactured by AstraZeneca, had previously been approved back in 2003 to be given by health care providers similar to other flu shots. Now the vaccinemaker has approval to ...
AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN) has received approval from the US Food and Drug Administration (FDA) for its FluMist influenza vaccine to be self-administered, marking a significant ...
FluMist approved for self-administration in the US Only influenza vaccine approved for self- or caregiver-administration at home, expanding options for influenza protection FluMist ...